Angioedema: Mechanisms, Subtypes, and Care

Angioedema represents a critical, potentially life-threatening vascular condition characterized by sudden, localized, non-pitting swelling of the deeper dermal, subcutaneous, and submucosal tissues. Affecting dynamic anatomical compartments such as the face, upper airway, gastrointestinal tract, and extremities, this clinical phenomenon bridges immunology, emergency medicine, and vascular biology. Understanding its heterogeneous etiologies—ranging from immunoglobulin E-mediated mast cell degranulation to bradykinin-driven enzymatic deficiencies—remains essential for timely diagnostic stratification and life-saving therapeutic intervention.

Angioedema

1. Concise Definition

Angioedema is an acute or recurrent, transient swelling of the deep dermis, subcutaneous tissues, or mucous membranes caused by a temporary increase in vascular permeability and extravasation of plasma into interstitial compartments. Unlike superficial urticaria, which involves the superficial dermis, angioedema involves deeper anatomical tissue planes, typically presents with poorly demarcated borders, and is often perceived as localized tension or pain rather than intense pruritus.

In clinical practice, angioedema manifests primarily via two distinct biochemical pathways: the histamine-mediated cascade (mast-cell-dependent) and the contact-kinin or kinin-kallikrein pathway leading to excess bradykinin. Mast cell-mediated variants are frequently accompanied by acute urticaria, bronchospasm, and pruritus, whereas kinin-mediated forms emerge indolently without wheals or itching, frequently involving the upper respiratory tract and visceral structures of the abdominal cavity.

Because laryngeal edema can progress swiftly to complete airway obstruction, angioedema constitutes a medical emergency requiring rapid clinical categorization to ensure proper deployment of targeted rescue therapies such as epinephrine, complement inhibitors, or bradykinin B2-receptor antagonists.

2. Etymology & Linguistic Origin

The term angioedema is an etymological composite derived from two classical ancient Greek roots. The initial component stems from the ancient Greek noun angeîon (αγγεῖον), meaning “vessel,” “receptacle,” or “small container,” which in modern biomedical nomenclature specifically denotes blood or lymphatic vessels. The second component originates from oídēma (οἴδημα), meaning “a swelling” or “tumor,” formed from the verb oidé&omacron; (οἰδέω), “to swell.”

Historically, the condition was referred to as “angioneurotic edema” throughout late nineteenth- and early twentieth-century medical texts, based on the erroneous hypothesis of nineteenth-century neuropathologists that the episodic vascular permeability was driven primarily by vasomotor neurosis or autonomic dysfunction. Modern molecular insights revealed the biochemical, immunological, and enzymatic determinants of the disease, prompting international consensus bodies to deprecate the adjective “neurotic” in favor of the precise physiological designation “angioedema.”

3. Pronunciation & Grammatical Form

Pronunciation: The word is pronounced phonetically as /ˌændʒioʊ.ɪˈdiːmə/ in Standard American English and /ˌændʒiəʊ.ɪˈdiːmə/ in Received Pronunciation (British English).

Grammatical Form: It is a singular, non-count (uncountable) noun, though it is frequently employed in clinical counts when describing distinct clinical episodes or specific nosological forms (e.g., “recurrent angioedemas” or “hereditary angioedemas”). The adjectival form is angioedematous (/ˌændʒioʊ.ɪˈdɛmətəs/), as in “angioedematous swelling of the epiglottis.” Variants such as angioneurotic edema persist solely as historical synonyms or obsolete taxonomy.

4. Detailed Conceptual Explanation

At its physiological core, angioedema represents a failure of local microvascular barrier function. The microvasculature, specifically the post-capillary venules, maintains fluid homeostasis through an intricate balance of hydrostatic pressure, oncotic pressure, and an intact endothelial barrier. Under normal conditions, continuous endothelial cell monolayers, interconnected by vascular endothelial (VE)-cadherin-mediated adherens junctions, prevent the uncontrolled transit of intravascular macromolecules into the interstitial space. In angioedema, potent endogenous vasoactive mediators trigger the disassembly of these endothelial intercellular junctions, forming transcellular and intercellular gaps that permit rapid plasma extravasation.

The clinical phenomenology of this fluid shifts directly corresponds to the tissue architecture of the involved sites. In tissues with abundant loose connective tissue—such as the periorbital regions, lips, tongue, genitalia, and uvula—plasma accumulation produces profound macroscopic disfigurement. In submucosal intestinal beds, fluid extravasation distends the bowel wall, resulting in transient intestinal ischemia, severe visceral pain, vomiting, and secondary ascites that can easily mimic an acute surgical abdomen. When localization occurs within the narrow confines of the laryngeal and supraglottic vestibule, progressive mechanical swelling can compress the upper airway within hours, precipitating asphyxiation if not rapidly recognized and mitigated.

Crucially, the clinical behavior and therapeutic responsiveness of angioedema depend on whether the underlying driver is histaminergic or non-histaminergic. Histamine-mediated angioedema evolves quickly, reaching its peak intensity within 1 to 6 hours, and commonly responds to interventions targeting the mast cell axis, including H1-antihistamines, systemic corticosteroids, and intramuscular epinephrine. Conversely, bradykinin-mediated angioedema develops more slowly over 12 to 36 hours, persists for several days, and is refractory to conventional allergic management, necessitating direct pharmacological blockade of the contact activation system or kallikrein-bradykinin cascade.

5. Historical Development

The systematic medical description of angioedema began in the latter half of the nineteenth century, though historical retrospectives suggest episodic non-inflammatory swellings had been observed since antiquity. In 1882, the German internist Heinrich Quincke documented the clinical syndrome of sudden, localized, transient edema across multiple anatomical sites, defining it as “acute circumscribed edema” (often immortalized eponymously as Quincke’s edema). Quincke accurately observed its transient nature, predilection for mucous membranes, and frequent lack of preceding trauma.

A critical milestone occurred in 1888 when the Canadian-American physician Sir William Osler published a landmark case series titled “Hereditary Angio-Neurotic Oedema.” Osler meticulously tracked a five-generation family affected by episodic swellings and recurrent abdominal pain, noting a dominant transmission pattern and high mortality from sudden suffocation. Osler’s pedigree demonstrated that certain forms of angioedema represented an inherited monogenic disorder with variable phenotypic penetrance.

The twentieth century brought definitive biochemical clarity. In 1963, Virginia Donaldson and Richard Evans made the transformative discovery that patients with hereditary angioedema suffered from an inherited deficiency or functional absence of C1 esterase inhibitor (C1-INH), an essential plasma serine protease inhibitor (serpin). Subsequent investigations throughout the 1980s and 1990s by researchers such as Allen Kaplan, Marco Cicardi, and Bruce Zuraw demonstrated that the terminal mediator responsible for vascular hyperpermeability in C1-INH deficiency was not histamine or an anaphylatoxin from the complement system, but rather the vasoactive nonapeptide bradykinin. This discovery paved the way for modern targeted pharmacotherapies, including plasma-derived and recombinant C1-INH concentrates, the plasma kallikrein inhibitor ecallantide, and the bradykinin B2-receptor antagonist icatibant.

6. Theoretical Foundations & Pathophysiology

The pathophysiology of angioedema is broadly organized into two core theoretical paradigms: the Mast Cell-Mediated Paradigm and the Kinin-Mediated Paradigm. Each framework is characterized by distinct molecular pathways, cellular interactions, and physiological consequences.

Under the mast cell-mediated framework, tissue-resident mast cells and basophils undergo degranulation triggered by either an IgE-dependent mechanism (e.g., classical type I hypersensitivity reactions to foods, venoms, or beta-lactam antibiotics) or non-IgE activation via Mas-related G protein-coupled receptor X2 (MRGPRX2), radiocontrast media, or physical stimuli. Upon degranulation, preformed histamine, alongside de novo synthesized leukotrienes (LTC4, LTD4, LTE4) and prostaglandin D2, binds to histamine H1 and H2 receptors on microvascular endothelial cells. This receptor engagement mobilizes intracellular calcium, activates myosin light-chain kinase, causes endothelial cell retraction, and increases vascular permeability. The clinical hallmark of this pathway is rapid onset, severe pruritus, and frequent concurrence with urticarial wheals.

Under the kinin-mediated framework, excessive generation or impaired degradation of bradykinin serves as the central pathophysiological event. Bradykinin is an inflammatory peptide cleaved from high-molecular-weight kininogen (HMWK) by the serine protease plasma kallikrein. This cascade is held in homeostatic equilibrium by C1 esterase inhibitor (which inhibits factor XIIa and kallikrein) and metalloproteinases such as angiotensin-converting enzyme (ACE), aminopeptidase P, and neutral endopeptidase (which rapidly degrade active kinins). When C1-INH is structurally deficient, functionally impaired, or when ACE is pharmacologically inhibited, uninhibited contact activation triggers massive bradykinin release. Bradykinin binds selectively to the constitutive bradykinin B2 receptor on endothelial surfaces, stimulating nitric oxide synthase and prostacyclin production, which breaks open endothelial tight junctions. This mechanism proceeds independently of mast cells, explaining the complete absence of urticaria and the futility of antihistamines or glucocorticoids in this subset.

7. Key Components, Types & Dimensions

Angioedema is classified nosologically into several primary types based on the primary mediator, genetic architecture, and triggering etiology:

• Histaminergic / Mast Cell-Mediated Angioedema: Driven by histamine and lipid mediators released from mast cells. Subdivided into:
  • Allergic Angioedema: Mediated by allergen-specific IgE cross-linking (e.g., peanuts, hymenoptera stings, beta-lactams).
  • Pseudoallergic / Non-IgE Angioedema: Triggered by non-immune degranulation or cyclooxygenase-1 (COX-1) inhibition by nonsteroidal anti-inflammatory drugs (NSAIDs), shifting arachidonic acid metabolism toward cysteinyl leukotrienes.
  • Chronic Spontaneous Angioedema: Episodic swelling occurring in tandem with or independent of chronic spontaneous urticaria, frequently autoimmune in origin (driven by IgG autoantibodies targeting FcεRI or IgE).
• Hereditary Angioedema (HAE): A rare, autosomal dominant genetic condition characterized by recurring, non-pruritic, non-urticarial swelling episodes. Subdivided into:
  • HAE Type I (approx. 85% of cases): Caused by mutations in the SERPING1 gene leading to decreased antigenic levels and low functional capacity of C1-INH.
  • HAE Type II (approx. 15% of cases): Caused by missense mutations in SERPING1 producing normal or elevated levels of a non-functional, mutant C1-INH protein.
  • HAE with Normal C1-INH (formerly HAE Type III): Rare variants caused by gain-of-function or structural mutations in genes such as F12 (factor XII), PLG (plasminogen), ANGPT1 (angiopoietin-1), KNG1 (kininogen 1), MYOF (myoferlin), or HS3ST6.
• Acquired Angioedema (AAE): An acquired deficiency of C1-INH, typically presenting after the fourth decade of life without family history. Strongly linked to B-cell lymphoproliferative disorders, monoclonal gammopathies of undetermined significance (MGUS), or autoantibodies directed against C1-INH.
• Drug-Induced Bradykinin-Mediated Angioedema: Most commonly precipitated by Angiotensin-Converting Enzyme (ACE) Inhibitors. Because ACE is the primary enzyme responsible for bradykinin catabolism, its pharmacological inhibition can trigger severe submucosal or subcutaneous edema in up to 0.5% of exposed patients, occasionally years after initiating therapy. Dipeptidyl peptidase-4 (DPP-4) inhibitors and neprilysin inhibitors can similarly exacerbate this risk.
• Idiopathic Non-Histaminergic Angioedema: Recurrent angioedema with normal complement panels, no identified genetic locus, and complete failure to respond to high-dose antihistamines.

8. Examples & Illustrative Cases

Case 1: The Histaminergic Acute Hypersensitivity Presentation
A 24-year-old male with an atopic background presents to the emergency room 35 minutes after eating a seafood meal. He reports rapid-onset perioral numbness, lip enlargement, bilateral periorbital edema, generalized urticaria over the trunk, and mild inspiratory stridor. This case illustrates classical IgE-mediated histaminergic angioedema. The rapid onset, associated pruritus, and presence of wheals warrant prompt treatment for anaphylaxis: intramuscular epinephrine administered into the anterolateral thigh, followed by intravenous H1/H2 receptor antagonists and systemic corticosteroids.

Case 2: The Latent ACE-Inhibitor-Induced Presentation
A 62-year-old female presents to the triage unit with prominent, asymmetric swelling of the tongue and lower lip that started gradually 14 hours earlier. She denies skin itching, hives, changes in diet, or insect stings. Her pharmacological history reveals she has taken lisinopril for systemic hypertension for over six years without prior complications. This case exemplifies drug-induced, bradykinin-mediated angioedema. Because kinin accumulation occurs independent of mast cell degranulation, epinephrine and steroids are minimally effective; management centers on maintaining a patent airway (including early fiberoptic intubation if progressive), discontinuing the ACE inhibitor permanently, and considering off-label bradykinin-targeted therapeutics.

Case 3: Unexplained Intestinal Hereditary Angioedema
A 19-year-old woman presents with recurrent, disabling episodes of severe, colicky abdominal pain accompanied by nausea, vomiting, and profound lethargy. Multiple abdominal ultrasounds and computed tomography (CT) scans during prior flares revealed transient duodenal edema, thickened bowel loops, and free peritoneal fluid, prompting exploratory laparoscopies that yielded no definitive surgical pathology. A comprehensive complement workup performed in a quiescent state reveals a C4 level of 4 mg/dL (markedly reduced) and a C1-INH functional activity of 22% (normal > 70%). These results confirm Hereditary Angioedema Type I, explaining her purely gastrointestinal presentations and illustrating how kinin-driven visceral edema can masquerade as an acute abdomen.

9. Measurement, Diagnosis & Assessment

The diagnostic workup of angioedema requires differentiating histaminergic pathways from kinin-mediated etiologies. The clinical history remains the primary screening tool, focusing on personal and family history of episodic swelling, presence or absence of concomitant urticaria, response to conventional antiallergic agents, and medication history (specifically ACE inhibitors, angiotensin receptor blockers, and NSAIDs).

Laboratory evaluation is dictated by clinical phenotype:

• Complement Profile: Serum Complement C4, C1-INH antigenic protein level, and C1-INH functional activity form the triad for evaluating suspected kinin-mediated disease. Complement C4 serves as an excellent screening test; in untreated HAE Types I and II, C4 is persistently depressed in approximately 98% of patients, even between attacks.
• C1q Measurement: Serum C1q levels help distinguish hereditary forms from acquired C1-INH deficiency. C1q is typically normal in HAE (Types I and II) but markedly depleted in Acquired Angioedema (AAE) due to immune complex-mediated consumption or anti-C1-INH autoantibodies.
• Genetic Testing: Targeted sequencing of SERPING1 identifies pathogenic variants in ambiguous HAE cases and enables prenatal screening. In suspected cases of HAE with normal C1-INH, comprehensive panels screen for mutations in F12, PLG, ANGPT1, and KNG1.
• Tryptase and Total IgE: Serum baseline and acute tryptase levels are drawn during suspected mast cell-mediated anaphylactic events to document mast cell activation.
• Severity and Quality of Life Metrics: Standardized tools such as the Angioedema Activity Score (AAS), the Angioedema Control Test (ACT), and the Angioedema Quality of Life Questionnaire (AE-QoL) objectively capture disease burden and treatment response.

10. Applications & Practical Significance

The distinction between mediator pathways directly governs acute emergency protocols and long-term prophylactic management. In clinical and emergency settings, misdiagnosing bradykinin-mediated angioedema as an allergic reaction frequently leads to clinical inertia, where clinicians repeatedly administer high doses of antihistamines, H2 blockers, and corticosteroids while the patient faces impending airway closure.

In kinin-mediated crises (such as HAE attacks or severe ACE-inhibitor-induced angioedema), specific pharmacological interventions are required:

• Airway Management: Because edema progresses rapidly, supraglottic and laryngeal swelling can distort anatomical landmarks, turning routine endotracheal intubation into a critical airway emergency. Early fiberoptic-assisted awake intubation or emergency cricothyroidotomy may be required.
• Targeted Acute Therapeutics: Intravenous plasma-derived C1-INH concentrates (e.g., Berinert, Cinryze) or recombinant C1-INH (Ruconest) replenish the depleted regulatory protein. The bradykinin B2-receptor antagonist icatibant (Firazyr) competitively blocks receptor binding, while the plasma kallikrein inhibitor ecallantide (Kalbitor) prevents ongoing bradykinin synthesis.
• Long-Term Prophylaxis: In patients with frequent HAE attacks, modern prophylactic standards emphasize targeted plasma kallikrein inhibition via monoclonal antibodies (lanadelumab) or small-molecule oral inhibitors (berotralstat), alongside subcutaneous C1-INH replacement, shifting clinical care from episodic rescue to near-complete disease control.

11. Research & Empirical Evidence

Contemporary clinical trials have transformed the treatment landscape for non-histaminergic angioedema. The HELP randomized clinical trial (Banerji et al., 2018) demonstrated the efficacy of lanadelumab, a fully human monoclonal antibody directed against active plasma kallikrein. Administered subcutaneously every two to four weeks, lanadelumab produced an 87% reduction in mean monthly HAE attack rates compared to placebo, with over 76% of patients achieving attack-free status during the study period. This confirmed that tonic inhibition of plasma kallikrein successfully mitigates vascular hyperpermeability without interfering with baseline hemostatic balance.

Parallel advancements in oral therapies were confirmed in the APeX-2 study (Zuraw et al., 2021), which evaluated berotralstat, a once-daily oral kallikrein inhibitor. The trial demonstrated significant reductions in monthly attack frequency and sustained improvements in patient-reported quality of life, offering a non-invasive alternative to lifelong intravenous or subcutaneous infusions.

Current translational research explores gene-editing and nucleic acid therapies. Early clinical trials investigating NTLA-2002, an in vivo CRISPR-Cas9 genome editing candidate targeting the KLKB1 gene (which encodes prekallikrein), have demonstrated durable reductions in circulating total plasma kallikrein and near-complete cessation of angioedema attacks following a single intravenous infusion. These molecular interventions highlight a potential shift from chronic suppressive management to permanent functional remission.

12. Cultural & Cross-Cultural Considerations

The clinical incidence, presentation, and diagnostic delay of angioedema vary significantly across global populations and healthcare infrastructures. Epidemiological studies demonstrate that ACE-inhibitor-induced angioedema occurs at a three- to five-fold higher rate in individuals of African ancestry compared to those of European descent. This discrepancy is partly attributable to polymorphisms in enzymes that metabolize non-kinin vasodilators (such as substance P and neurokinin A) and differences in endogenous vascular sensitivity to bradykinin, underscoring the need for tailored anti-hypertensive prescribing practices.

Conversely, diagnostic delays in hereditary forms of angioedema reveal deep global healthcare disparities. In high-income countries equipped with centralized health systems, the average interval between symptom onset and formal diagnosis of HAE remains between 8 and 10 years; in developing economies with limited access to specialized complement assays (such as C1-INH functional testing), this delay often extends beyond two decades. Furthermore, in many resource-limited settings where targeted on-demand therapies like icatibant or C1-INH concentrates are unavailable or cost-prohibitive, clinicians must rely on fresh frozen plasma (FFP)—which contains both C1-INH and substrate kininogen, carrying a theoretical risk of transiently worsening an attack—or attenuated androgens (e.g., danazol), which are complicated by dose-dependent hepatotoxicity and virilization.

13. Criticisms, Debates & Limitations

Despite substantial clinical progress, several diagnostic and therapeutic controversies persist across the angioedema spectrum:

• Efficacy of HAE Therapeutics in ACE-Inhibitor Angioedema: Although the molecular target (excess bradykinin) is shared between HAE and ACE-inhibitor-induced angioedema, clinical trials investigating the off-label efficacy of icatibant and C1-INH concentrates in ACE-inhibitor angioedema have yielded contradictory results. Several double-blind, randomized trials failed to demonstrate statistically significant reductions in time to complete symptom resolution compared to placebo, fueling debate over the cost-effectiveness and pharmacological predictability of these expensive agents in the emergency setting.
• The Nomenclature and Diagnosis of HAE with Normal C1-INH: Substantial controversy surrounds patients who present with clear clinical characteristics of non-histaminergic angioedema but maintain normal C4, normal C1-INH antigenic levels, and intact C1-INH activity. Despite expanding genetic panels (identifying F12, PLG, and other variants), a large percentage of these individuals test negative on all known genetic panels, leaving them without definitive molecular markers or standardized, evidence-based management plans.
• Safety and Teratogenicity of Historical Prophylactics: The continued global reliance on attenuated androgens (danazol, stanozolol) for long-term HAE prophylaxis remains a focal point of clinical debate. While highly effective and inexpensive, their long-term use frequently leads to adverse events, including peliosis hepatis, hepatic adenomas, dyslipidemia, virilization in females, and absolute contraindication in pregnancy. Access to newer, safer targeted biologics remains sharply constrained by economic barriers.

14. Related Terms & Distinctions

• Urticaria: Characterized by circumscribed, elevated, erythematous, highly pruritic edematous wheals that arise within the superficial dermis. Angioedema differs by affecting the deep dermis and subcutaneous/submucosal tissues; it is non-pitting, poorly demarcated, causes localized discomfort rather than itching, and can compromise the airway or bowel.
• Cellulitis: An acute, painful, spreading bacterial infection of the deep dermis and subcutaneous tissue characterized by intense erythema, warmth, fever, and leukocytosis. Angioedema lacks systemic signs of infection, develops more rapidly (minutes to hours vs. days), and resolves without desquamation or antibiotic treatment.
• Superior Vena Cava (SVC) Syndrome: Oncological or vascular compression of the superior vena cava producing persistent, bilateral facial, neck, and upper extremity swelling accompanied by venous distension across the chest wall. Angioedema is transient, episodic, and not associated with persistent venous engorgement or structural mediastinal masses.
• Anaphylaxis: A severe, life-threatening, multi-system systemic hypersensitivity reaction involving two or more organ systems (e.g., cutaneous, respiratory, cardiovascular, gastrointestinal). Angioedema is a localized physiological finding that may manifest as a single symptom within an anaphylactic crisis or occur as an isolated, non-anaphylactic phenomenon.

15. Summary & Key Takeaways

Angioedema is an episodic, localized swelling of the deep subcutaneous and submucosal tissue layers driven by transient microvascular hyperpermeability. Pathophysiologically, it bifurcates into two main categories: mast cell/histamine-mediated and contact system/bradykinin-mediated mechanisms. Histaminergic angioedema develops rapidly, frequently co-occurs with pruritus and urticaria, and responds well to antihistamines, corticosteroids, and epinephrine. Bradykinin-mediated angioedema (encompassing HAE, acquired C1-INH deficiency, and ACE-inhibitor-induced presentations) develops insidiously, lacks urticaria and itching, spares responsiveness to standard antiallergic agents, and presents substantial risk of fatal laryngeal obstruction or acute abdominal symptoms.

Accurate clinical stratification, targeted diagnostic complement testing (C4, C1-INH level and function), and timely deployment of mechanism-specific therapies (such as C1-INH concentrates, icatibant, and modern kallikrein inhibitors) are essential to prevent mortality and optimize quality of life for affected patients.

References

• Banerji, A., Riedl, M. A., Bernstein, J. A., Cicardi, M., Longhurst, H. J., Zuraw, B. L., Busse, P. J., Anderson, J., Magerl, M., Martinez-Saguer, I., Davis-Lorton, M., Zanichelli, A., Wedner, H. J., Tachdjian, R., Jacobs, J. S., Yang, W. H., Lumry, W. R., Baker, J., Lockey, R. F., … Maurer, M. (2018). Effect of lanadelumab compared with placebo on prevention of attacks in patients with hereditary angioedema: A randomized clinical trial. JAMA, 320(21), 2108–2121. https://doi.org/10.1001/jama.2018.16773
• Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., Longhurst, H. J., Lumry, W. R., Maurer, M., Moldovan, D., Pelbart, J., Powrie, F., Reshef, A., Ritchie, B., Rochels, F., … Zuraw, B. L. (2014). Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy, 69(5), 602–616. https://doi.org/10.1111/all.12380
• Donaldson, V. H., & Evans, R. R. (1963). A biochemical abnormality in heredoneurotic edema: Absence of serum inhibitor of C’ 1-esterase. The American Journal of Medicine, 35(1), 37–44. https://doi.org/10.1016/0002-9343(63)90162-1
• Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N. A., Boccon-Gibod, I., Bork, K., Bouillet, L., Busse, P. J., Caballero, T., Cancian, M., Charignon, D., Christiansen, S. C., Cicardi, M., Craig, T., Csuka, D., … Zuraw, B. L. (2022). The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Allergy, 77(7), 1961–1990. https://doi.org/10.1111/all.15214
• Zuraw, B. L., Lumry, W. R., Johnston, D. T., Aygören-Pürsün, E., Banerji, A., Bernstein, J. A., Jacobs, J. S., Tachdjian, R., Wedner, H. J., Anderson, J., Baker, J., Craig, T., Davis-Lorton, M., Farkas, H., Katelaris, C. H., Longhurst, H. J., Magerl, M., Martinez-Saguer, I., Moldovan, D., … Maurer, M. (2021). Oral berotralstat for the prevention of hereditary angioedema attacks: A randomized, controlled trial. Journal of Allergy and Clinical Immunology, 148(1), 164–172. https://doi.org/10.1016/j.jaci.2020.10.023